Clinical trials: Breast Cancer, Metastatic
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a…
- Trial name
- Amelia-1 (NCT05455619)
- Testing
- Evexomostat
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- SynDevRx, Inc.
Anal Cancer, Anxiety Disorder
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may…
- Conditions
- Anal Cancer, Anxiety Disorder, Breast Cancer, Depression
- Trial name
- NCT00896467
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009763
- Testing
- filgrastim, monoclonal antibody m170, cyclosporine
- Where
- United States
- Sponsor
- University of California, Davis
Leptomeningeal Disease, Glioblastoma
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or…
- Conditions
- Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer
- Trial name
- GUIDE-CNS (NCT07689721)
- Testing
- CSF ctDNA-Guided Clinical Management
- Volunteers
- 77 people
- Sponsor
- Alireza Mansouri
Breast Cancer
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
The goal in this Phase 1 dose-escalation trial of the anti-IL-6R monoclonal antibody tocilizumab in combination with trastuzumab and pertuzumab in subjects with metastatic HER2 positive breast cancer is to determine the safety…
- Trial name
- NCT03135171
- Testing
- Trastuzumab, Pertuzumab, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Beast Cancer
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
This phase II trial studies how well exemestane and cyclophosphamide work in treating patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and human epidermal growth factor receptor…
- Trial name
- NCT01963481
- Testing
- Exemestane, Cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Breast Cancer
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic…
- Trial name
- NCT01740336
- Testing
- GDC-0941, Paclitaxel
- Where
- 97 sites in United States, Australia and 6 more
- Volunteers
- 183 people
- Sponsor
- Genentech, Inc.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT06434064
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Locally Advanced or Metastatic Breast Cancer
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
- Trial name
- NCT05744687
- Testing
- SPH4336 Tablets 400mg
- Where
- 9 sites in China
- Volunteers
- 374 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors, Breast Cancer
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended…
- Trial name
- NCT06775236
- Testing
- SYS6010 jnjection, monotherapy chemotherapy, SYH2051 tablets
- Volunteers
- 410 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Metastatic Breast Cancer, Lung Metastases
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have…
- Conditions
- Metastatic Breast Cancer, Lung Metastases, Liver Metastases
- Trial name
- OX40 Breast (NCT01862900)
- Testing
- MEDI6469
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Providence Health & Services
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Spinal Neoplasms
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
The goal of this clinical research study is to find out if stereotactic spine radiotherapy is safe and effective in the treatment of metastatic spine tumors.
- Trial name
- NCT00508443
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Phase I Combination w/ Epirubicin
Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment.
- Trial name
- NCT00322374
- Testing
- Ixabepilone, Epirubicin
- Where
- 2 sites in France, Italy
- Volunteers
- 42 people
- Sponsor
- R-Pharm
Estrogen Receptor Negative, Estrogen Receptor Positive
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative
- Trial name
- NCT01281163
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Breast Cancer, Metastatic Colon Cancer
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Metastatic Colon Cancer, Metastatic Prostate Cancer
- Trial name
- NCT02655952
- Testing
- Foxy-5
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 17 people
- Sponsor
- WntResearch AB
Post Menopausal Breast Cancer
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer…
- Trial name
- EVEREXES (NCT03176238)
- Testing
- everolimus, exemestane
- Where
- 55 sites in Australia, India and 11 more
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of cancer cells. Letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00014638
- Testing
- letrozole
- Where
- 20 sites in United States
- Sponsor
- Novartis
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03218826
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.